Fundsmith Investment Services LTD. increased its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 2.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,206,414 shares of the company’s stock after acquiring an additional 30,691 shares during the quarter. Zoetis comprises 2.8% of Fundsmith Investment Services LTD.’s holdings, making the stock its 14th largest position. Fundsmith Investment Services LTD.’s holdings in Zoetis were worth $151,791,000 as of its most recent SEC filing.
Several other institutional investors also recently added to or reduced their stakes in ZTS. Brighton Jones LLC increased its stake in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares during the period. Empowered Funds LLC increased its stake in Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after buying an additional 657 shares during the period. Intech Investment Management LLC increased its stake in Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after buying an additional 1,224 shares during the period. Sivia Capital Partners LLC increased its stake in Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after buying an additional 1,422 shares during the period. Finally, Glenview Trust co grew its holdings in Zoetis by 11.8% during the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after acquiring an additional 506 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.
Insider Activity
In other news, Director Paul Bisaro purchased 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 11,650 shares of company stock worth $886,384. Corporate insiders own 0.22% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Research Report on Zoetis
Zoetis Stock Down 0.8%
Shares of Zoetis stock opened at $79.28 on Wednesday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a 1 year low of $72.38 and a 1 year high of $164.32. The firm’s 50-day moving average is $95.41 and its two-hundred day moving average is $113.49. The stock has a market cap of $33.24 billion, a price-to-earnings ratio of 13.15, a PEG ratio of 1.25 and a beta of 0.75.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the prior year, the business posted $1.48 earnings per share. The firm’s quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.
Zoetis Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.
Zoetis News Roundup
Here are the key news stories impacting Zoetis this week:
- Negative Sentiment: The flood of class-action reminders highlights alleged investor harm and creates another headline risk for Zoetis, which can weigh on sentiment while litigation moves forward. Article Title
- Negative Sentiment: Several law firms allege securities-law violations tied to the same class period, reinforcing uncertainty around prior disclosures and potentially keeping pressure on the stock. Article Title
- Neutral Sentiment: The company’s recent earnings backdrop remains a separate concern: Zoetis previously missed both EPS and revenue estimates, which may continue to influence investor caution.
Zoetis Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Articles
- Five stocks we like better than Zoetis
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
